Skip to content
Melanocortin receptor agonists

Melanotan-2 vs PT-141

The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.

What it is
Melanotan-2Experimental tan-boosting peptide that also acts on libido and appetite; few studies in humans so far.
PT-141Approved medicine for low sexual desire disorder in women before menopause, acting through the nervous system.
Type
Melanotan-2Cyclic heptapeptide (MC1-5R agonist)
PT-141Melanocortin receptor agonist (MC3R/MC4R)
Structure
Melanotan-2Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
PT-141Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular weight
Melanotan-2~1024 Da
PT-141~1025 Da
Target area
Melanotan-2Skin pigmentation, libido
PT-141Disorder of reduced sexual desire
Storage
Melanotan-22–8°C (reconstituted)
PT-1412–8°C (reconstituted)
Stability
Melanotan-225–30 days (reconstituted)
PT-14125–30 days (reconstituted)

Melanotan-2 or PT-141: what is the difference?

The two peptides are almost the same: their structures differ only at the very end of the chain. Melanotan-2 switches on several melanocortin receptors, so it affects tanning, sexual desire and appetite; the PT-141 entry names two receptors (MC3R, MC4R), and its target is low sexual desire disorder. PT-141 was in fact developed because Melanotan-2 also affected sexual desire as a side effect. The biggest difference is their status: Melanotan-2 is an experimental compound with only a few small human studies, while PT-141 was approved by the FDA in 2019 as Vyleesi, for low sexual desire in premenopausal women.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant